JPMorgan raises target for BioCryst Pharmaceuticals stock

Published on 10/05/2026 at 00:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 2026 revenue hit USD 218.25 million, up 33.60 percent year over year. JPMorgan set USD 13.00 for BioCryst Pharmaceuticals stock.

BCRX, US09058V1035, Illustration mit AI erstellt.

JPMorgan raised its BioCryst Pharmaceuticals (ISIN US09058V1035) price target from USD 12.00 to USD 13.00 on September 30, 2026, while maintaining a neutral rating, according to MarketBeat. The change gives the latest analyst view a concrete number, but it still leaves the target below the broader consensus estimate.

JPMorgan sets a USD 13.00 target

The target moved from USD 12.00 to USD 13.00, a 8.33 percent increase based on JPMorgan's previous target. The bank kept its neutral rating, creating a more cautious signal than the wider analyst average.

MarketBeat reported on September 15, 2026, that seven of 12 covering firms rated BioCryst a Buy and five recommended Hold. The average 12-month target stood at USD 20.40, materially above JPMorgan's USD 13.00 view.

Q2 revenue reaches USD 218.25 million

BioCryst reported USD 218.25 million in revenue for the second quarter of 2026, up 33.60 percent from the same quarter a year earlier, according to MarketBeat. Adjusted earnings per share reached USD 0.30 against a USD 0.15 consensus estimate, a USD 0.15 beat for the same reporting period.

The company says its latest quarterly earnings materials cover Q2 2026, while its investor-relations profile identifies ORLADEYO as a commercialized oral, once-daily treatment for hereditary angioedema. BioCryst also describes a pipeline focused on oral small-molecule and injectable protein therapies for rare diseases, according to BioCryst Pharmaceuticals.

Nasdaq range keeps the risk visible

BioCryst traded at USD 8.17 on Nasdaq at 4:00 p.m. EDT on October 2, 2026, with a 52-week range of USD 6.00 to USD 11.22. Its market capitalization was USD 2.1 billion on that date. The share price stood 27.19 percent below the 52-week high, a measurable gap between the current valuation and the yearly peak.

Prior close was EUR 7.20

The prior close at Lang & Schwarz was EUR 7.20 on October 2, 2026. The fact pattern leaves the analyst target revision, the Q2 revenue growth and the distance from the yearly high as the key figures for assessing BioCryst stock.